Sartorius Stedim Biotech Investor Relations

First-Half 2016 Results

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, discussed the company's results with analysts and Investors in a teleconference.

Download Presentation (1.4 MB)

Download Replay (11.5 MB)

First-Quarter 2016 Results

Full-Year 2015 Results

Facts & Figures

Download a brief overview of Sartorius Stedim Biotech and its current economic development.

Fact Sheet H1|2016 (261 KB)


First half of 2016: Sartorius Stedim Biotech continues strong performance

€ in millions unless otherwise specified1st half 20161st half 2015Growth in %Growth in %const. fx Sales revenue508.8422.020.622.3EMEA1231.5192.520.321.5Americas1187.9149.325.927.3Asia |...[more]

Date 25.07.2016     Category Corporate, Sartorius Stedim Biotech

Sartorius Stedim BioOutsource Introduces New Released N-Glycan Assay

In-depth profiling of IgG glycosylation coupled with ADCC assays enables generation of robust biosimilar comparability data [more]

Date 07.07.2016     Category Products, Sartorius Stedim Biotech

Sartorius Stedim Biotech Share (DIM)

Get in touch

Petra Kirchhoff

Andreas Theisen